Amneal Pharmaceuticals, Inc. (AMRX)
17.44
-0.43
(-2.41%)
USD |
NASDAQ |
Sep 04, 16:00
17.46
+0.02
(+0.09%)
Pre-Market: 20:00
Amneal Pharmaceuticals Research and Development Expense (Quarterly) : 39.02M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 39.02M |
| March 31, 2026 | 38.38M |
| December 31, 2025 | 36.23M |
| September 30, 2025 | 63.35M |
| June 30, 2025 | 47.96M |
| March 31, 2025 | 40.04M |
| December 31, 2024 | 54.26M |
| September 30, 2024 | 61.10M |
| June 30, 2024 | 36.05M |
| March 31, 2024 | 39.30M |
| December 31, 2023 | 46.09M |
| September 30, 2023 | 41.38M |
| June 30, 2023 | 37.80M |
| March 31, 2023 | 38.69M |
| December 31, 2022 | 41.91M |
| September 30, 2022 | 50.24M |
| June 30, 2022 | 50.75M |
| March 31, 2022 | 52.80M |
| December 31, 2021 | 51.87M |
| September 30, 2021 | 48.93M |
| June 30, 2021 | 52.86M |
| March 31, 2021 | 48.18M |
| December 31, 2020 | 53.46M |
| September 30, 2020 | 44.52M |
| June 30, 2020 | 45.57M |
| Date | Value |
|---|---|
| March 31, 2020 | 36.38M |
| December 31, 2019 | 48.05M |
| September 30, 2019 | 38.12M |
| June 30, 2019 | 48.02M |
| March 31, 2019 | 53.86M |
| December 31, 2018 | 56.65M |
| September 30, 2018 | 42.30M |
| June 30, 2018 | 50.34M |
| March 31, 2018 | 44.21M |
| December 31, 2017 | 43.49M |
| September 30, 2017 | 41.32M |
| June 30, 2017 | 47.18M |
| March 31, 2017 | 22.49M |
| December 31, 2016 | 20.53M |
| September 30, 2016 | 20.12M |
| June 30, 2016 | 21.75M |
| March 31, 2016 | 19.02M |
| December 31, 2015 | 26.39M |
| September 30, 2015 | 18.63M |
| June 30, 2015 | 17.00M |
| March 31, 2015 | 14.96M |
| December 31, 2014 | 17.13M |
| September 30, 2014 | 18.98M |
| June 30, 2014 | 21.25M |
| March 31, 2014 | 21.74M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Liquidia Corp. | 16.88M |
| Eli Lilly & Co. | 3.819B |
| Viatris, Inc. | 245.20M |
| Pfizer Inc. | 2.746B |
| Harmony Biosciences Holdings, Inc. | 46.60M |